Todays Market Nifty 8638.50 (-27.80) (-0.32%)

Sensex 28051.86 (-156.76) (-0.56%)

Pidilite Industries standalone net profit rises 20.29% in the June 2016 quarter

Net profit of Pidilite Industries rose 20.29% to Rs 272.38 crore in the quarter ended June 2016 as against Rs 226.43 crore during the previous quarter ended June 2015. Sales rose 4.95% to Rs 1362.67 crore in the quarter ended June 2016 as against Rs 1298.36 crore during the previous quarter ended June 2015.

Karnataka Bank standalone net profit rises 11.16% in the June 2016 quarter

Net profit of Karnataka Bank rose 11.16% to Rs 121.54 crore in the quarter ended June 2016 as against Rs 109.34 crore during the previous quarter ended June 2015. Total Operating Income rose 2.57% to Rs 1260.60 crore in the quarter ended June 2016 as against Rs 1229.05 crore during the previous quarter ended June 2015.

Todays Market Nifty 8666.30 (+ 50.50) (+0.59%)

Sensex 28208.62 (+184.29) (+0.66%)

Syndicate Bank standalone net profit declines 73.80% in the June 2016 quarter

Net profit of Syndicate Bank declined 73.80% to Rs 79.13 crore in the quarter ended June 2016 as against Rs 301.98 crore during the previous quarter ended June 2015. Total Operating Income rose 0.72% to Rs 5864.63 crore in the quarter ended June 2016 as against Rs 5822.65 crore during the previous quarter ended June 2015.

Punjab National Bank standalone net profit declines 57.49% in the June 2016 quarter

Net profit of Punjab National Bank declined 57.49% to Rs 306.36 crore in the quarter ended June 2016 as against Rs 720.71 crore during the previous quarter ended June 2015. Total Operating Income declined 3.82% to Rs 11574.94 crore in the quarter ended June 2016 as against Rs 12034.69 crore during the previous quarter ended June 2015

Todays Market Nifty 8615.80 (+25.15) (+0.29%)

Sensex 28024.33 (+47.81) (+0.17%)

Bajaj Auto consolidated net profit rises 13.77% in the June 2016 quarter

Net profit of Bajaj Auto rose 13.77% to Rs 1039.70 crore in the quarter ended June 2016 as against Rs 913.86 crore during the previous quarter ended June 2015. Sales rose 2.78% to Rs 5643.61 crore in the quarter ended June 2016 as against Rs 5490.85 crore during the previous quarter ended June 2015.

Shriram Transport Finance gains after announcing good Q1 results

The result was announced during market hours today, 27 July 2016.

Meanwhile, the BSE Sensex was up 64.33 points, or 0.23% to 28,040.85.

On BSE, so far 1.15 lakh shares were traded in the counter, compared with an average volume of 35,000 shares in the past two weeks. The stock hit high of Rs 1,265.95 and low of Rs 1,205.

Shriram Transport Finance Companys net interest income rose 18.53% to Rs 1346.10 crore in Q1 June 2016 over Q1 June 2015. Total Assets under Management as on 30 June 2016 stands at Rs 74808.46 crore as compared to Rs 60531.72 as on 30 June 2015.

Shriram Transport Finance Company is the largest asset financing NBFC. The company is a leader in organized financing of pre-owned trucks with strategic presence in 5-12 year old trucks.

Glenmark Pharma gains after receiving USFDA approval for a drug

The announcement was made before market hours today, 27 July 2016.

Meanwhile, the S&P BSE Sensex was up 189.28 points or 0.68% at 28,165.80.

On BSE, so far 6,446 shares were traded in the counter, compared with an average volume of 40,502 shares in the past one quarter. The stock hit a high of Rs 849.70 and a low of Rs 838.55 so far during the day. The stock hit a record high of Rs 1,261.95 on 21 August 2015. The stock hit a 52-week low of Rs 671.50 on 12 February 2016. The stock had outperformed the market over the past one month till 26 July 2016, rising 10.43% compared with 5.98% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, advancing 1.37% as against Sensexs 7.57% rise.

The large-cap company has an equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals announced that Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Potassium Chloride Extended-Release Tablets USP, 10 mEq (750 mg) and 20 mEq (1500 mg), the generic version of K-Dur (Potassium Chloride) Extended-Release Tablets, 10 and 20 mEq of Merck Sharp and Dohme Corp. The generic version is no longer being marketed in the United States.

According to IMS health sales data for the 12 month period ending May 2016, the K-Dur (Potassium Chloride) Extended-Release Tablets, 10 and 20 mEq market achieved annual sales of around $283.20 million in the US.

On a consolidated basis, Glenmark Pharmaceuticals net profit jumped 1516.31% to Rs 171.49 crore on 24% rise in net sales to Rs 2174.02 crore in Q4 March 2016 over Q4 March 2015.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation (asthma/COPD, rheumatoid arthritis etc.) and pain (neuropathic pain and inflammatory pain).

Todays Market Nifty 8590.65 (-  45.00) (-0.52%)

Sensex 27976.52 (-118.82) (-0.42%)

Dr Reddys Laboratories consolidated net profit declines 77.25% in the June 2016 quarter

Net profit of Dr Reddys Laboratories declined 77.25% to Rs 146.20 crore in the quarter ended June 2016 as against Rs 642.50 crore during the previous quarter ended June 2015. Sales declined 14.05% to Rs 3212.30 crore in the quarter ended June 2016 as against Rs 3737.20 crore during the previous quarter ended June 2015.